-+ 0.00%
-+ 0.00%
-+ 0.00%

Evolus Partners With Symatese To Commence Distribution Of Nuceiva In France

Benzinga·07/09/2025 12:04:08
Listen to the news
  • Launching into this key growth market as part of the company's geographic expansion strategy
  • Evolus to provide Nuceiva® to French medical aesthetics healthcare professionals through its partnership with Symatese enabling direct order and delivery

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinum toxin type A) in France.

Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.